Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
Date:8/3/2009

ely.

Second Half 2009 Financial Outlook

MAP Pharmaceuticals' cash, cash equivalents, short-term investments and accounts receivables as of June 30, 2009 provide operating capital for at least the next twelve months. MAP Pharmaceuticals currently expects to have lower operating expenses in the second half of 2009 compared to the first half of 2009.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate and future cash usage. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the following: the enrollment, conduct, completion and reporting of clinical trials, risks related to the failure to achieve favorable clinical outcomes and to have the company's LEVADEX produ
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... (PRWEB) August 01, 2014 Summer is here, ... most active during the summer, and they can be a ... is ready to help all their customers get rid of ... 3,000 and 6,000 eggs in the summer, which is why ... live in tall grass and woodland areas and carry a ...
(Date:8/1/2014)... Illinois (PRWEB) August 01, 2014 As ... across the country, Ronald E. Johnson, Jr. has been ... by AndroGel and other testosterone medications. Since the Fall ... Johnson, P.S.C. have worked diligently to investigate and prosecute ... pulmonary embolisms, and blood clots as a result of ...
(Date:8/1/2014)... Writing down fears, emotions and the benefits of a ... cancer survivors, according to a study conducted by a ... "The key to developing an expressive writing intervention is ... journal recording facts and events. Writing a journal can ... evidence to determine whether it,s effective or not," said ...
(Date:8/1/2014)... 2014 Growing prevalence of chronic ... reforms are boosting healthcare market growth, although a ... and increasing generic consumption is a major challenge. ... in 2013, having grown at a Compound Annual ... implementation of the Health Transformation Program (Saglikta Donus, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Hot off the ... destination spa category of the World’s Best Awards by ... a month-long celebration of National Relaxation Day (technically August 15). ... series of MAJOR experts to help guests celebrate relaxation throughout ... it is for health and wellness to carve out time ...
Breaking Medicine News(10 mins):Health News:Tis the Season for Tick Prevention 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4
... of remittances shines spotlight on companies engaged in ... those efforts, - Economic issues top ... of origin for the 3x1 and 4+1 programs. - Secure,delivery, seen as most important ... would encourage senders to use companies that ...
... Health and Human Services published an update to its ... and Dependence,which contains revised and improved recommendations to providers ... quitting. The,guideline also confirms that there has never been ... With the release of these new guidelines, smokers ...
... following is a,statement by William V. Corr, Executive ... smoking cessation released today by the U.S. Public,Health ... 45 million,smokers that they have more scientifically proven ... their health than ever before, including safe,and effective ...
... An updated clinical,practice guideline released today by the ... medication treatments that are effective for,helping people quit ... JAMA includes,a commentary that urges clinicians to use ... use of tobacco., Treating Tobacco Use and ...
... results of sub-analyses of dose-titration study and long-term, ... open-label study presented today, WASHINGTON, ... in children, Attention Deficit Hyperactivity Disorder,(ADHD) is now known to be ... lifespan(1). In the US, the overall,prevalence of ADHD in adults is ...
... it helps ease the shock of trauma, study finds ... from post-traumatic stress disorder may ultimately benefit from a ... new research suggests. , The study findings are preliminary. ... a potent way to help PSTD patients through the ...
Cached Medicine News:Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:New Smoking Cessation Guideline Confirms That Now is the Time to Quit Smoking 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 4Health News:New Evidence Provides Clinicians With Better Tools to Help Smokers Quit 2Health News:New Evidence Provides Clinicians With Better Tools to Help Smokers Quit 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 4Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 5Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 6Health News:Virtual Reality Therapy May Help PTSD Patients 2Health News:Virtual Reality Therapy May Help PTSD Patients 3
(Date:8/1/2014)... 2014 Research and Markets ... Medical Biosensors Market 2014-2018" report to their ... Medical biosensors are used to analyze ... These biosensors monitor health status, disease betterment, and ... They are cost-effective and user-friendly devices. Also, they ...
(Date:8/1/2014)...  NxStage Medical, Inc. (Nasdaq: NXTM ), a ... Jeffrey H. Burbank , Chief Executive Officer, and Mathew ... th Annual Canaccord Genuity Growth Conference being held at ... Wednesday, August 13 th at 4:30 p.m. ET.  A ... http://ir.nxstage.com/ .  About NxStage Medical ...
(Date:8/1/2014)... , Aug. 1, 2014 Dyadic International, Inc. ... and proprietary technologies are used to develop, manufacture and ... chemical, biopharmaceutical and industrial enzyme industries, announced today that ... quarter ended June 30, 2014 after market close on ... call that day at 5:00 p.m. Eastern Time to ...
Breaking Medicine Technology:Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... Ala., May 7 BioCryst Pharmaceuticals (Nasdaq: BCRX ... first quarter 2009 financial results will be released on Friday, ... a conference call and Web cast at 8:30 a.m. Eastern ... on the Company,s programs. The call will be led ...
... The Abbott RealTi m e HIV-1 Assay and Abbott ... protocol for viral load testing in HIV/AIDS clinical trials sponsored ... This recommendation was made by the Cross-Network Laboratory Focus Group ... HIV/AIDS clinical trials networks. The LFG recently issued a consensus ...
Cached Medicine Technology:BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 3